In a nutshell This study was carried out to assess the long-term outcomes of men diagnosed with prostate cancer (PC) undergoing active surveillance (AS) and factors that predicted the risk of their cancer spreading (metastasizing). The authors found that AS is a safe and viable option for men with low-risk and carefully-selected intermediate-risk...
Read More
In a nutshell This study aimed to evaluate the use of irreversible electroporation (IRE) in the treatment of prostate cancer. This study found that IRE had low side-effect rates and promising outcomes. Some background Irreversible electroporation (IRE) uses high-energy pulses of electricity to destroy cancer cells. The brand name for...
Read MoreIn a nutshell This study aimed to investigate the outcomes of intermediate risk-risk prostate cancer after different treatments. This study concluded that prostate surgery might have a higher survival than radiotherapy. Some background There a several options to treat intermediate-risk prostate cancer (IR-PC). Radical prostatectomy (RP; surgery to...
Read MoreIn a nutshell This phase 3 trial is examining the effectiveness and safety of low dose rate (LDR) vs high dose rate (HDR) prostate brachytherapy (BT) for patients with prostate cancer (PC). The main outcome to be measured will be the quality of life in terms of urinary symptoms. This trial is recruiting in British Columbia,...
Read More
In a nutshell This trial evaluates the effectiveness of radiation therapy delivered from outside the body for the treatment of prostate cancer. The main outcomes of this trial are the number of patients who have no damage to genital or urinary organs and survival without cancer. This trial is taking place in various sites across the USA and...
Read More
In a nutshell This study examined rates of biochemical relapse after using intraoperatively planned low-dose-rate prostate brachytherapy using an automated delivery system (IO-LDRB) in men with low and intermediate stage prostate cancer. This study found that rates of biochemical relapse were low after treatment. Some background...
Read More
In a nutshell This study aimed to evaluate active surveillance as an option in intermediate stage prostate cancer. It found that it should be based on multiple criteria, but is still a viable option. Gleason score, PSA, volume of cancer in biopsy, age, and MRI results should all play a role in making the decision. Some background Active...
Read More
In a nutshell The authors aimed to determine the safety and efficacy of focal therapy compared to active surveillance in men with low-risk prostate cancer. The authors concluded that focal therapy was a safe and effective treatment option in men with low-risk prostate cancer. The also suggested that this treatment could be an option to avoid more...
Read More
In a nutshell This study aimed to investigate the relationship between patient age and active surveillance outcomes in prostate cancer (PC). This study concluded that younger patients undergoing AS were less likely to see an increased Gleason score and progression. Some background Early stage PC that has not yet spread is often not treated...
Read MoreIn a nutshell The authors aimed to determine how anxiety and uncertainty affects men with prostate cancer who are undergoing active surveillance. The authors concluded that uncertainty and urinary complications promote anxiety in men on active surveillance for prostate cancer. They also recommend patient education and management of urinary...
Read More
In a nutshell The aim of this study was to see if ultrasounds could be used as a tool to monitor low-risk prostate cancer patients in active surveillance. It was concluded that ultrasounds can be used to monitor changes in prostate cancer, and could extend the time between biopsies. Some background Low-risk prostate cancer is cancer that has not...
Read More
In a nutshell This study examined the role of active surveillance in the management of intermediate-risk prostate cancer. Researchers concluded that active surveillance is a safe management method for selected patients with favorable intermediate-risk disease. Men with more aggressive cancer cells may benefit from active treatment early on. Some...
Read More
